Aegerter H, Lambrecht BN. The Pathology of Asthma: what is obstructing our view? Annu Rev Pathol. 2023;18:387–409.

Article  CAS  PubMed  Google Scholar 

Chiu C-Y, Cheng M-L, Chiang M-H, Wang C-J, Tsai M-H, Lin G. Integrated metabolic and microbial analysis reveals host–microbial interactions in IgE-mediated childhood asthma. Sci Rep. 2021;11:23407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Habib N, Pasha MA, Tang DD. Current understanding of Asthma Pathogenesis and biomarkers. Volume 11. Cells; 2022.

Manti S, Piedimonte G. An overview on the RSV-mediated mechanisms in the onset of non-allergic asthma. Front Pead, 10 (2022).

Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunology: Pract. 2020;8:429–40.

Google Scholar 

Zhang X, Xu Z, Wen X, Huang G, Nian S, Li L, Guo X, Ye Y, Yuan Q. The onset, development and pathogenesis of severe neutrophilic asthma. Immunol Cell Biology. 2022;100:144–59.

Article  Google Scholar 

Komlósi ZI, van de Veen W, Kovács N, Szűcs G, Sokolowska M, O’Mahony L, Akdis M, Akdis CA. Cellular and molecular mechanisms of allergic asthma. Mol Aspects Med, 85 (2022).

Qian L, Mehrabi Nasab E, Athari SM, Athari SS. Mitochondria Signaling pathways in allergic asthma. J Investig Med. 2023;70:863–82.

Article  Google Scholar 

Fukuda Y, Horita N, Aga M, Kashizaki F, Hara Y, Obase Y, Niimi A, Kaneko T, Mukae H, Sagara H. Efficacy and safety of macrolide therapy for adult asthma: a systematic review and meta-analysis. Respiratory Invest. 2024;62:206–15.

Article  CAS  Google Scholar 

Pollock J, Chalmers JD. The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulm Pharmacol Ther. 2021;71:102095.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Undela K, Adatia A, Rowe BH, Ferrara G. Macrolides and Asthma Therapy. in: Macrolides as Immunomodulatory Agents, Springer,; 2024. pp. 149–60.

Amin S, Soliman M, McIvor A, Cave A, Cabrera C. Usage patterns of short-acting β2-agonists and inhaled corticosteroids in asthma: a targeted literature review. J Allergy Clin Immunology: Pract. 2020;8:2556–64. e2558.

Google Scholar 

Sousa-Pinto B, Louis R, Anto JM, Amaral R, Sá-Sousa A, Czarlewski W, Brussino L, Canonica GW, Loureiro CC, Cruz A. Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma. Pulmonology: A MASK-air study; 2023.

Google Scholar 

Caramori G, Nucera F, Mumby S, Lo Bello F, Adcock IM. Corticosteroid resistance in asthma: Cellular and molecular mechanisms. Mol Aspects Med, 85 (2022).

Sun J, Li Y. Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases. Pediatr Res. 2022;91:1036–42.

Article  CAS  PubMed  Google Scholar 

Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184:1469–85.

Article  CAS  PubMed  Google Scholar 

Agache I, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Chu DK, Del Giacco S, Eiwegger T, Flood B, Firinu D, Gern JE, Hamelmann E, Hanania N, Hernández-Martín I, Knibb R, Mäkelä M, Nair P, O’Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez L, de Llano O, Pfaar S, Quirce J, Sastre M, Shamji J, Schwarze O, Palomares M, Jutel. EAACI Biologicals Guidelines—Recommendations for severe asthma, Allergy, 76 (2020) 14–44.

Papaioannou AI, Fouka E, Ntontsi P, Stratakos G, Papiris S. Paucigranulocytic asthma: potential pathogenetic mechanisms, clinical features and therapeutic management. J Personalized Med, 12 (2022).

Jiang Y, Yan Q, Liu C-X, Peng C-W, Zheng W-J, Zhuang H-F, Huang H-t, Liu Q, Liao H-L, Zhan S-F, Liu X-H, Huang X-F. Insights into potential mechanisms of asthma patients with COVID-19: a study based on the gene expression profiling of bronchoalveolar lavage fluid. Comput Biol Med, 146 (2022).

Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler M.E., Brightling C.E., Griffiths J.M., Hellqvist Å., Bowen K., Kaur P., Almqvist G., Ponnarambil S., Colice G. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800–9.

Article  CAS  PubMed  Google Scholar 

Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res, 21 (2020).

Smolinska S, Antolín-Amérigo D, Popescu F-D, Jutel M. Thymic Stromal Lymphopoietin (TSLP), its isoforms and the interplay with the epithelium in Allergy and Asthma. Int J Mol Sci. 2023;24:12725.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin Y-C, Lin Y-C, Tsai M-L, Liao W-T, Hung C-H. TSLP regulates mitochondrial ROS-induced mitophagy via histone modification in human monocytes. Cell Bioscience. 2022;12:32.

Article  PubMed  PubMed Central  Google Scholar 

Theofani E, Tsitsopoulou A, Morianos I, Semitekolou M. Severe asthmatic responses: the impact of TSLP. Int J Mol Sci. 2023;24:7581.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kabata H, Flamar A-L, Mahlakõiv T, Moriyama S, Rodewald H-R, Ziegler SF, Artis D. Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation. Mucosal Immunol. 2020;13:626–36.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ebina-Shibuya R, Leonard WJ. TSLP‐targeting therapy: beyond allergy? Clin Translational Med, 13 (2023).

Kurihara Y, Tashiro H, Konomi Y, Sadamatsu H, Ihara S, Takamori A, Kimura S, Sueoka-Aragane N, Takahashi K. Thymic stromal lymphopoietin contributes to ozone-induced exacerbations of eosinophilic airway inflammation via granulocyte colony-stimulating factor in mice. Allergology International; 2023.

Caminati M, Buhl R, Corren J, Hanania NA, Kim H, Korn S, Lommatzsch M, Martin N, Matucci A, Nasser SM. Tezepelumab in patients with allergic and eosinophilic asthma, Allergy, (2023).

Van Hulst G, Bureau F, Desmet CJ. Eosinophils as drivers of severe eosinophilic asthma: endotypes or plasticity? Int J Mol Sci. 2021;22:10150.

Article  PubMed  PubMed Central  Google Scholar 

Oppenheimer J, Hoyte FC, Phipatanakul W, Silver J, Howarth P, Lugogo NL. Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions, annals of Allergy. Asthma Immunol. 2022;129:169–80.

Article  CAS  Google Scholar 

Pelaia C, Pelaia G, Crimi C, Maglio A, Gallelli L, Terracciano R, Vatrella A. Tezepelumab: a potential new biological therapy for severe refractory asthma. Int J Mol Sci. 2021;22:4369.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nordenmark LH, Hellqvist Å, Emson C, Diver S, Porsbjerg C, Griffiths JM, Newell JD, Peterson S, Pawlikowska B, Parnes JR. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2:EVIDoa2300135.

Article  PubMed  Google Scholar 

Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, Brightling CE, Griffiths JM, Hellqvist Å, Bowen K. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800–9.

Article  CAS  PubMed  Google Scholar 

Parnes J, Molfino NA, Colice G, Martin U, Corren J, Menzies-Gow A. Targeting TSLP in Asthma. J Asthma Allergy. 2022;15:749–65.

Article  PubMed  PubMed Central  Google Scholar 

Gon Y, Maruoka S, Mizumura K. Omalizumab and IgE in the control of severe allergic asthma. Front Pharmacol. 2022;13:839011.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Smith-Norowitz TA, Loeffler J, Huang Y, Klein E, Norowitz YM, Hammerschlag MR, Joks R, Kohlhoff S. Chlamydia pneumoniae immunoglobulin E antibody levels in patients with asthma compared with non-asthma. Heliyon, 6 (2020).

Gevaert P, Wong K, Millette LA, Carr TF. The role of IgE in upper and lower airway disease: more than just allergy! Clin Rev Allergy Immunol, (2022) 1–16.

Stokes J, Casale TB. The relationship between IgE and allergic disease, Uptodate. Available online: https://www.uptodate.com/contents/the-relationship-between-ige-and-allergic-disease, (2022).

Cheng S-L. Immunologic pathophysiology and airway remodeling mechanism in severe asthma: focused on IgE-mediated pathways. Volume 11. Diagnostics; 2021. p. 83.

McDowell PJ, Heaney LG. Different endotypes and phenotypes drive the heterogeneity in severe asthma. Allergy. 2019;75:302–10.

Article  PubMed  Google Scholar 

Ridolo E, Pucciarini F, Nizi MC, Makri E, Kihlgren P, Panella L, Incorvaia C. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, in. Taylor & Francis; 2020.

Fu Z, Xu Y, Cai C. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis. J Asthma. 2021;58:1350–8.

Article  CAS  PubMed  Google Scholar 

Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K. Roles of omalizumab in various allergic diseases. Allergology Int. 2020;69:167–77.

Article  CAS  Google Scholar 

Kotoulas SC, Tsiouprou I, Fouka E, Pataka A, Papakosta D, Porpodis K. Omalizumab: an optimal choice for patients with severe allergic asthma. J Personalized Med. 2022;12:165.

Article  Google Scholar 

Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24:777–92.

Article  CAS  PubMed  Google Scholar 

Lai J-F, Thompson LJ, Ziegler SF. TSLP drives acute TH2-cell differentiation in lungs. J Allergy Clin Immunol. 2020;146:1406–e14181407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, Johnston J, Molfino N, Parnes JR, Megally A, Colice G, Brightling CE. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Med. 2021;9:1299–312.